Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This review examines the potential of CAR-T cell therapy as a transformative treatment for refractory autoimmune diseases, highlighting its mechanisms, clinical challenges, and promising strategies for precision immunotherapy despite issues like complex manufacturing and antigen escape.

This review synthesizes current evidence on therapies for dissecting cellulitis of the scalp, noting that biologics show promise for treatment-resistant cases, though systemic retinoids remain the first-line therapy.

This case series found that topical janus kinase inhibitors, along with oral fexofenadine and vitamin D supplementation, significantly reduced disease severity in Black pediatric patients with alopecia areata, demonstrating substantial hair regrowth and minimal adverse side effects.

This narrative review suggests that while corticosteroids and Janus kinase inhibitors may be effective for treating ophiasis-pattern alopecia areata in both adults and children, the limited age-specific evidence underscores the need for further research to confirm their efficacy and safety across age groups.

In this retrospective study, dupilumab treatment in young children with alopecia areata and atopic features was linked to full hair regrowth without serious adverse events, though findings from this small cohort should be interpreted cautiously.

In this review, summarized findings suggest that emerging targeted immunotherapies may offer promising treatment options for alopecia areata by addressing the breakdown of hair follicle immune privilege.

In this review, researchers reported that pyroptosis, a type of inflammatory cell death linked to inflammasome activity, is a key factor in the pathogenesis of alopecia areata and may present new therapeutic opportunities, though most treatments are still in early research stages.

This study reviewed 18 studies on the effects of ustekinumab and vedolizumab on alopecia in ulcerative colitis patients, finding varied outcomes ranging from significant hair regrowth to increased hair loss, with 65.5% experiencing regrowth and potential therapy benefits needing further exploration in larger trials.

This study reviewed a corticosteroid treatment regimen for a 52-year-old woman with extensive alopecia areata, showing significant hair regrowth and sustained remission over 12 months, suggesting oral mini-pulse therapy as a viable alternative for those ineligible for JAK inhibitors.

This guideline by the British Association of Dermatologists reviews managing alopecia areata and provides 56 recommendations but reports no new clinical results.

This case series observed that five Black pediatric patients with moderate to severe alopecia areata showed significant hair regrowth and minimal disease activity after treatment with topical JAK inhibitors, vitamin D supplementation, and antihistamines, with additional therapies in some cases.

This review highlights that although advancements in alopecia areata treatments, such as Janus kinase inhibitors and combination therapies, show promise, further research is necessary to validate their long-term safety and efficacy.

This study described trichilemmal cysts, firm lumps that form from blocked hair follicles, typically found on the scalp but also less commonly on other body parts, affecting less than 10% of the population and possibly inherited as an autosomal dominant trait.

This study found that adding cyclophosphamide to glucocorticoid treatment for pemphigus patients led to earlier remission, with 89.5% achieving remission within 4 months compared to 73.9% with glucocorticoids alone, suggesting significant steroid-sparing effects and improved clinical outcomes.

This review reports that three JAK inhibitors—baricitinib, ritlecitinib, and deuruxolitinib—have gained FDA approval for treating alopecia areata due to their demonstrated efficacy in fostering hair regrowth in clinical trials.

In this study, a 32-year-old female with alopecia areata experienced significant symptom relief after receiving traditional Ayurvedic treatments, including Virechana, Pracchana, and Rasayana therapies, alongside external application of Chakramarda. The protocol was reported to be simple, cost-effective, and highly efficacious.

This study reports that a patient with severe, treatment-resistant alopecia areata experienced sustained hair regrowth and emotional improvement over 24 months following individualized homeopathic treatment, suggesting homeopathy may be a viable therapeutic option when conventional treatments fail.

This study highlights that early detection and tailored treatment based on kidney biopsy classification are crucial in managing lupus nephritis to prevent progression to end-stage kidney disease, with a focus on saving nephron cells.

This study provides initial insights into the use of JAK inhibitors for CTCL, reporting some cases of symptom improvement, but highlights the need for further research on their association with CTCL development and safety.

This case report describes significant therapeutic effects from Tofacitinib Citrate Sustained-Release Tablets in a patient with Alopecia Areata, while highlighting the economic burden of long-term treatment.

In this case series, treatment with clascoterone cream 1% was reported to be effective and well tolerated for diverse acne vulgaris patients, improving clinical outcomes whether used alone or in combination with other therapies, and addressing various other skin conditions.

This study describes a 62-year-old male with trichodaganomania, an urge to bite his mustache hair, who was treated with counseling and placebo medication, highlighting the need for a comprehensive treatment approach including potential psychological and psychiatric interventions if symptoms recur.

This case series involving 10 patients treated with clascoterone cream 1% for acne vulgaris found it effective and well-tolerated, regardless of severity, age, gender, or ethnicity, and noted additional benefits for related skin conditions.

This review discusses the promising role of JAK inhibitors in managing alopecia areata, reporting significant hair regrowth and acceptable safety profiles but noting the need for further research on dosing and long-term safety.

This systematic review and meta-analysis found that bimatoprost, especially when used with NB-UVB phototherapy, FxCO2 laser, or mometasone, may be an effective and well-tolerated treatment option for vitiligo, achieving significant patient satisfaction and repigmentation, despite some limitations like small sample sizes and high costs.

This study reports a case where cyclosporine effectively treated a 51-year-old woman with idiopathic follicular mucinosis resistant to other therapies, suggesting its potential as an option for refractory cases.

This review reports that transgender patients undergoing hormone therapy may experience acne differently, necessitating tailored treatments that take into account skin dryness and the potential need for maintenance topical treatments.

This article reviews treatment options for Alopecia Areata, concluding that topical corticosteroids are effective for mild cases, while systemic therapies are advised for moderate to severe cases.

This review found that various dermatological procedures for Seborrheic Dermatitis, such as phototherapy and laser treatments, showed significant efficacy in small cohorts with high patient satisfaction, but highlighted the need for further research to standardize protocols and evaluate long-term outcomes.

In this study, baricitinib was used as monotherapy to treat a 21-year-old woman with severe alopecia areata, resulting in significant hair regrowth and reduced alopecia severity within three months, suggesting its effectiveness and potential as a robust treatment option for this condition.